Restart Life Sciences Past Earnings Performance
Past criteria checks 0/6
Restart Life Sciences has been growing earnings at an average annual rate of 23.5%, while the Biotechs industry saw earnings growing at 19.3% annually. Revenues have been declining at an average rate of 21.7% per year.
Key information
23.5%
Earnings growth rate
37.8%
EPS growth rate
| Biotechs Industry Growth | 51.1% |
| Revenue growth rate | -21.7% |
| Return on equity | n/a |
| Net Margin | n/a |
| Last Earnings Update | 30 Jun 2024 |
Revenue & Expenses Breakdown
How Restart Life Sciences makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 0 | -1 | 1 | 0 |
| 31 Mar 24 | 0 | -1 | 1 | 0 |
| 31 Dec 23 | 0 | -1 | 1 | 0 |
| 30 Sep 23 | 0 | -2 | 1 | 0 |
| 30 Jun 23 | 0 | -2 | 1 | 0 |
| 31 Mar 23 | 0 | -2 | 2 | 0 |
| 31 Dec 22 | 0 | -2 | 2 | 0 |
| 30 Sep 22 | 0 | -2 | 2 | 0 |
| 30 Jun 22 | 0 | -3 | 2 | 1 |
| 31 Mar 22 | 0 | -3 | 2 | 1 |
| 31 Dec 21 | 0 | -3 | 2 | 1 |
| 30 Sep 21 | 0 | -21 | 2 | 1 |
| 30 Jun 21 | 0 | -20 | 2 | 0 |
| 31 Mar 21 | 0 | -26 | 2 | 0 |
| 31 Dec 20 | 0 | -25 | 2 | 0 |
| 30 Sep 20 | 0 | -7 | 1 | 0 |
| 30 Jun 20 | 0 | -7 | 1 | 0 |
| 31 Mar 20 | 0 | -1 | 1 | 0 |
| 31 Dec 19 | 0 | -1 | 1 | 0 |
| 30 Sep 19 | 0 | -2 | 1 | 0 |
| 30 Jun 19 | 0 | -2 | 2 | 0 |
| 31 Mar 19 | 0 | -2 | 2 | 0 |
| 31 Dec 18 | 0 | -4 | 3 | 0 |
| 30 Sep 18 | 0 | -4 | 3 | 0 |
| 30 Jun 18 | 0 | -4 | 3 | 0 |
| 31 Mar 18 | 0 | -4 | 3 | 0 |
| 31 Dec 17 | 0 | -2 | 1 | 0 |
| 30 Sep 17 | 0 | -3 | 2 | 0 |
| 30 Jun 17 | 0 | -2 | 2 | 0 |
| 31 Mar 17 | 0 | -2 | 1 | 0 |
| 31 Dec 16 | 0 | -2 | 1 | 0 |
| 30 Sep 16 | 0 | -1 | 1 | 0 |
| 30 Jun 16 | 0 | -1 | 1 | 0 |
| 31 Mar 16 | 0 | -1 | 1 | 0 |
| 31 Dec 15 | 0 | -1 | 1 | 0 |
| 30 Sep 15 | 0 | -2 | 1 | 0 |
| 30 Jun 15 | 0 | -2 | 1 | 0 |
| 31 Mar 15 | 0 | -2 | 1 | 0 |
| 31 Dec 14 | 0 | -2 | 0 | 0 |
| 30 Sep 14 | 0 | 0 | 0 | 0 |
| 30 Jun 14 | 0 | 0 | 0 | 0 |
| 31 Mar 14 | 0 | 0 | 0 | 0 |
Quality Earnings: HEAL is currently unprofitable.
Growing Profit Margin: HEAL is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: HEAL is unprofitable, but has reduced losses over the past 5 years at a rate of 23.5% per year.
Accelerating Growth: Unable to compare HEAL's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: HEAL is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: HEAL's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.